Future research should aim to unravel how ATF4 activity is dynamically regulated by glutamine flux and how this interplay affects treatment responsiveness across diverse cancer types, ultimately paving the way for more effective, personalized therapeutic strategies. This evidence concerns the gene ATF4 and cancer.